{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Disoproxil+Fumarate&page=2", "query": { "intervention": "Tenofovir Disoproxil Fumarate", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 307, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Disoproxil+Fumarate&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Disoproxil+Fumarate&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T17:59:23.930Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02431247", "title": "A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immunodeficiency Virus Type 1, Human" ], "interventions": [ { "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC", "type": "DRUG" }, { "name": "DRV/COBI FDC", "type": "DRUG" }, { "name": "FTC/TDF FDC", "type": "DRUG" }, { "name": "D/C/F/TAF FDC - Matching Placebo", "type": "DRUG" }, { "name": "FTC/TDF FDC Matching Placebo", "type": "DRUG" }, { "name": "DRV/COBI FDC Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Sciences Ireland UC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 725, "start_date": "2015-07-06", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431247" }, { "nct_id": "NCT06630299", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "Antiretroviral Combinations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-08", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630299" }, { "nct_id": "NCT00051831", "title": "Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Enfuvirtide", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2003-10", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 6, "location_summary": "Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00051831" }, { "nct_id": "NCT00711009", "title": "Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Infection" ], "interventions": [ { "name": "lopinavir/ritonavir (LPV/r)", "type": "DRUG" }, { "name": "emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)", "type": "DRUG" }, { "name": "raltegravir (RAL)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2008-07", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711009" }, { "nct_id": "NCT03205696", "title": "Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Antiretrovirals", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "12 Years to 24 Years" }, "enrollment_count": 101, "start_date": "2017-08-01", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2025-03-25", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 3, "location_summary": "Los Angeles, California • New Orleans, Louisiana", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03205696" }, { "nct_id": "NCT02121795", "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Allowed third antiretroviral agent", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2014-05-06", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02121795" }, { "nct_id": "NCT04375800", "title": "Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus (HIV) Infection" ], "interventions": [ { "name": "Doravirine", "type": "DRUG" }, { "name": "2 NRTIs", "type": "DRUG" }, { "name": "DOR/3TC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Weeks to 11 Years" }, "enrollment_count": 84, "start_date": "2021-02-03", "completion_date": "2034-04-11", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 2, "location_summary": "Aurora, Colorado • Atlanta, Georgia", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375800" }, { "nct_id": "NCT01449929", "title": "Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "dolutegravir 50 mg OAD", "type": "DRUG" }, { "name": "darunavir 800mg OAD", "type": "DRUG" }, { "name": "ritonavir 100mg OAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 488, "start_date": "2011-10-31", "completion_date": "2016-12-26", "has_results": true, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01449929" }, { "nct_id": "NCT00224445", "title": "Boosted Atazanavir and Truvada Given Once-Daily - BATON Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Truvada", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2005-09", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 1, "location_summary": "Foster City, California", "locations": [ { "city": "Foster City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00224445" }, { "nct_id": "NCT02258581", "title": "Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "GS-4774", "type": "DRUG" }, { "name": "GS-9620", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate (TDF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2014-12-09", "completion_date": "2017-08-14", "has_results": false, "last_update_posted_date": "2017-10-03", "last_synced_at": "2026-10-04T17:59:23.930Z", "location_count": 16, "location_summary": "Sacramento, California • San Diego, California • San Francisco, California + 13 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258581" } ] }